您的位置: 首页 > 农业专利 > 详情页

Bifunctional fusion protein targeting CD47 and PD-l1
专利权人:
Taizhou Mabtech Pharmaceutical Co.; Ltd
发明人:
GUO, Yajun
申请号:
AU2017439776
公开号:
AU2017439776A1
申请日:
2017.11.20
申请国别(地区):
AU
年份:
2020
代理人:
摘要:
A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPα and the binding of PD-L1 to PD-1, can not only activate macrophages to devour tumor cells and promote antigen presentation in innate immunity, but also promote tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充